Tests etentamig with pomalidomide in relapsed or refractory multiple myeloma
Tests etentamig plus pomalidomide against standard treatments in adults with myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Szombathely, HungarySee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose multiple myeloma came back or did not respond to treatment, after 1 to 3 earlier treatment lines that included lenalidomide.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory multiple myeloma (the disease came back or did not respond to treatment).
- Earlier treatment
- Must have had at least 1 and no more than 3 prior lines of therapy, including lenalidomide. Must not have had earlier BCMA-directed T-cell engager therapy (bispecific or trispecific).
Main reasons for not taking part
- Earlier BCMA-directed T-cell engager therapy (bispecific or trispecific)
- Known myeloma in the central nervous system
- Another active cancer in the past 3 years (with some exceptions)
- Serious kidney, nerve, mental health, hormone, metabolic, immune, heart, lung or liver disease within the last 6 months
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
- Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
- Has a doctor told you that you have myeloma in the brain or in the fluid and membranes around the brain and spinal cord, now or in the past?
Source: NCT07728188, who can take part
Where in Hungary
- Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 283136Szombathely, HungaryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AbbVie
- Trial code
- NCT07728188EU 2026-525596-11-00
- Record updated
- 27 July 2026
- Original description
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide.Read full original descriptionShow less
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide.
Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide.
Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig injections plus oral pomalidomide or investigator's choice of SAT: SC daratumumab, oral pomalidomide, and oral/ IV dexamethasone (DPd); SC daratumumab, IV carfilzomib, and oral/IV dexamethasone (DKd); or SC teclistamab monotherapy. The total study duration is approximately 75 months
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Inclusion: Diagnosis of relapsed or refractory (RR) multiple myeloma (MM); Prior treatment with at least one and no more than three prior lines of therapy, including lenalidomide; Adequate organ function and performance status.
Exclusion: Prior B-cell maturation antigen (BCMA) directed T-cell engager therapy (bispecific or trispecific); Known history of other active malignancies within the past 3 years (with specific exceptions); Clinically significant conditions (renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months); Known central nervous system involvement of MM.